Table 1. Features of LNT, SIF and SIST.
| Marker (compartment)* | SIFs | SISTs | LNTs | References |
| LAMP1 (LE/Lys) | + | − | − | [18] |
| Scamp3 | +/− | + | − | [19] |
| T3SS-2 effector | + | + | + | [15], [17], [19], [23], [28], [32], [40], [41], [42] |
| EEA1 | − | n.d. | − | [43] |
| Rab5 (EE) | − | n.d. | − | [33] |
| Rab7 (LE) | + | n.d. | − | [33] |
| Rab9 (LE) | − | n.d. | − | |
| vATPase (LE/Lys) | + | − | + | [15] |
| Yip3 (LE) | − | n.d. | − | |
| Syntaxin 7 (LE) | n.d. | n.d. | − | |
| LBPA (LE) | + | n.d. | − | [33] |
| CD63 (LE/Lys) | + | − | − | [15] |
| Mannose 6-Phosphate Receptor (LE, TGN) | − | n.d. | − | [44], [45] |
| VPS26 (TGN) | − | n.d. | − | |
| Syntaxin 6 (TGN) | − | n.d. | − | |
| P230 (TGN) | − | n.d. | − | |
| GM 130 (cis Golgi) | − | n.d. | − | |
| Calreticulin (ER) | − | n.d. | − | |
| Calnexin (ER) | − | n.d. | − | |
| Dynein (P150glued) | − | n.d. | − | [13] |
| Cholesterol | + | n.d. | + | [33] |
| Susceptibility | ||||
| Nocodazole | + | + | + | [19], [35], [46] |
| Cytochalasin D | − | n.d. | − | [35], [46] |
| Brefeldin A | − | + | − | [19], [33] |
| SKIP RNAi | + | n.d. | − | [13] |
EE, early endosome; ER, endoplasmic reticulum; LE, late endosome; LE/Lys, late endosome/lysosome; TGN, trans-Golgi network.
n.d., not determined.